Accueil Ernstrade Bourse Actualite Stock



Acrux Limited is an Australian-based company. The Company is engaged in the development and commercialization of healthcare products. The Company derives its revenue from developing and commercialising products using a technology to administer drugs through the skin. AXIRON is a transdermal male testosterone replacement therapy being developed by the Company for global registration and commercialization. AXIRON is in Phase III development, the product is indicated for the treatment of low testosterone in men (hypogonadism), and is applied to the axilla (armpit), in much the same way as deodorants or antiperspirants. The Company’s subsidiaries include, Acrux DDS Pty Ltd, Fempharm Pty Ltd, Acrux Pharma Pty Ltd, Acrux Commercial Pty Ltd and Cosmeceutic Solutions Pty Ltd.          

Copyright  2017